Do analysts prefer TCRT or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, TCRT or BIVI?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is TCRT or BIVI more profitable?

BioVie's return on equity of -101.15% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% BioVie N/A -101.15% -90.18%

Do analysts prefer HYPD or BIVI?

Hyperion DeFi currently has a consensus price target of $6.95, indicating a potential upside of 123.47%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, research analysts clearly believe Hyperion DeFi is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hyperion DeFi 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HYPD or BIVI more profitable?

Hyperion DeFi's return on equity of -91.59% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% BioVie N/A -101.15% -90.18%

Do analysts rate DWTX or BIVI?

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 705.37%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, DWTX or BIVI?

BioVie is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A BioVie N/A N/A -$17.54M -$2.45 N/A

Is DWTX or BIVI more profitable?

BioVie's return on equity of -101.15% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -108.57% -30.28% BioVie N/A -101.15% -90.18%

Do analysts recommend BIVI or TIL?

Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 753.82%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts plainly believe Instil Bio is more favorable than BioVie. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings and valuation, BIVI or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is BIVI or TIL more profitable?

Instil Bio's return on equity of -39.76% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Instil Bio N/A -39.76% -22.38%

Do analysts rate INCR or BIVI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, INCR or BIVI?

InterCure has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.76 -$10.37M $0.03 36.33 BioVie N/A N/A -$17.54M -$2.45 N/A

Is INCR or BIVI more profitable?

InterCure's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A BioVie N/A -101.15% -90.18%

BioVie (BIVI) Competitors

$1.95 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.51%)

As of 07/2/2026 06:44 PM Eastern

Compare

BIVI vs. TCRT, HYPD, DWTX, TIL, and INCR

Should you buy BioVie stock or one of its competitors? MarketBeat compares BioVie with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioVie include Alaunos Therapeutics (TCRT), Hyperion DeFi (HYPD), Dogwood Therapeutics (DWTX), Instil Bio (TIL), and InterCure (INCR). These companies are all part of the "pharmaceutical products" industry.

How does BioVie compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market. Comparatively, BioVie has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

In the previous week, Alaunos Therapeutics had 2 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Alaunos Therapeutics and 0 mentions for BioVie. BioVie's average media sentiment score of 0.00 beat Alaunos Therapeutics' score of -0.30 indicating that BioVie is being referred to more favorably in the news media.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
BioVie	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

BioVie's return on equity of -101.15% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
BioVie	N/A	-101.15%	-90.18%

Summary

Alaunos Therapeutics and BioVie tied by winning 5 of the 10 factors compared between the two stocks.

How does BioVie compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Hyperion DeFi has a beta of 2.49, suggesting that its share price is 149% more volatile than the broader market. Comparatively, BioVie has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Hyperion DeFi's return on equity of -91.59% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
BioVie	N/A	-101.15%	-90.18%

BioVie has lower revenue, but higher earnings than Hyperion DeFi. BioVie is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810K	58.21	-$45.31M	-$9.95	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Hyperion DeFi currently has a consensus price target of $6.95, indicating a potential upside of 123.47%. Given Hyperion DeFi's stronger consensus rating and higher possible upside, research analysts clearly believe Hyperion DeFi is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Hyperion DeFi had 2 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Hyperion DeFi and 0 mentions for BioVie. Hyperion DeFi's average media sentiment score of 0.88 beat BioVie's score of 0.00 indicating that Hyperion DeFi is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperion DeFi	Positive
BioVie	Neutral

Summary

Hyperion DeFi beats BioVie on 12 of the 14 factors compared between the two stocks.

How does BioVie compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

BioVie's return on equity of -101.15% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-108.57%	-30.28%
BioVie	N/A	-101.15%	-90.18%

BioVie is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

Dogwood Therapeutics has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, BioVie has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 1 mentions for Dogwood Therapeutics and 0 mentions for BioVie. Dogwood Therapeutics' average media sentiment score of 0.00 equaled BioVie'saverage media sentiment score.

Company	Overall Sentiment
Dogwood Therapeutics	Neutral
BioVie	Neutral

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 705.37%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 0.9% of BioVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Dogwood Therapeutics beats BioVie on 8 of the 12 factors compared between the two stocks.

How does BioVie compare to Instil Bio?

BioVie (NASDAQ:BIVI) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

4.6% of BioVie shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Instil Bio's return on equity of -39.76% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Instil Bio	N/A	-39.76%	-22.38%

Instil Bio has a consensus price target of $66.00, suggesting a potential upside of 753.82%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts plainly believe Instil Bio is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioVie has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

Instil Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

In the previous week, BioVie's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
BioVie	Neutral
Instil Bio	Neutral

Summary

Instil Bio beats BioVie on 7 of the 10 factors compared between the two stocks.

How does BioVie compare to InterCure?

InterCure (NASDAQ:INCR) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, InterCure had 1 more articles in the media than BioVie. MarketBeat recorded 1 mentions for InterCure and 0 mentions for BioVie. InterCure's average media sentiment score of 0.98 beat BioVie's score of 0.00 indicating that InterCure is being referred to more favorably in the media.

Company	Overall Sentiment
InterCure	Positive
BioVie	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
BioVie	N/A	-101.15%	-90.18%

InterCure has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, BioVie has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market.

InterCure has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.76	-$10.37M	$0.03	36.33
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A

8.3% of InterCure shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 0.2% of InterCure shares are owned by company insiders. Comparatively, 0.9% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

InterCure beats BioVie on 10 of the 11 factors compared between the two stocks.

Get BioVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIVI vs. The Competition

Export

Metric	BioVie	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.71M	$3.10B	$7.18B	$12.47B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.80	20.06	28.02	24.70
Price / Sales	N/A	355.18	538.82	97.75
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.20	4.32	10.96	6.46
Net Income	-$17.54M	$64.45M	$3.57B	$337.01M
7 Day Performance	0.26%	2.97%	2.12%	1.69%
1 Month Performance	21.88%	6.83%	5.25%	3.81%
1 Year Performance	-79.73%	29.07%	33.29%	23.90%

BioVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIVI BioVie	0.3068 of 5 stars	$1.95 flat	N/A	-79.7%	$14.71M	N/A	N/A	10	Gap Up
TCRT Alaunos Therapeutics	0.782 of 5 stars	$2.16 +0.5%	N/A	-58.5%	$52.51M	N/A	N/A	40	News Coverage Gap Up
HYPD Hyperion DeFi	3.4239 of 5 stars	$3.71 +7.5%	$5.65 +52.3%	-80.5%	$52.29M	$810K	N/A	40	Analyst Forecast
DWTX Dogwood Therapeutics	2.7411 of 5 stars	$1.54 -0.6%	$12.00 +679.2%	-69.1%	$52.13M	N/A	N/A	5	Gap Up
TIL Instil Bio	1.3289 of 5 stars	$7.56 +0.8%	$66.00 +773.0%	-72.6%	$50.87M	N/A	N/A	410

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIVI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioVie (BIVI) Competitors

BIVI vs. TCRT, HYPD, DWTX, TIL, and INCR

How does BioVie compare to Alaunos Therapeutics?

Summary

How does BioVie compare to Hyperion DeFi?

Summary

How does BioVie compare to Dogwood Therapeutics?

Summary

How does BioVie compare to Instil Bio?

Summary

How does BioVie compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioVie (BIVI) Competitors

BIVI vs. TCRT, HYPD, DWTX, TIL, and INCR

How does BioVie compare to Alaunos Therapeutics?

Which has stronger valuation and earnings, TCRT or BIVI?

Which has more volatility and risk, TCRT or BIVI?

Does the media favor TCRT or BIVI?

Do analysts prefer TCRT or BIVI?

Do institutionals and insiders have more ownership in TCRT or BIVI?

Is TCRT or BIVI more profitable?

Summary

How does BioVie compare to Hyperion DeFi?

Which has more risk and volatility, HYPD or BIVI?

Do insiders & institutionals have more ownership in HYPD or BIVI?

Is HYPD or BIVI more profitable?

Which has higher valuation & earnings, HYPD or BIVI?

Do analysts prefer HYPD or BIVI?

Does the media favor HYPD or BIVI?

Summary

How does BioVie compare to Dogwood Therapeutics?

Is DWTX or BIVI more profitable?

Which has stronger earnings and valuation, DWTX or BIVI?

Which has more volatility and risk, DWTX or BIVI?

Does the media refer more to DWTX or BIVI?

Do analysts rate DWTX or BIVI?

Do insiders and institutionals have more ownership in DWTX or BIVI?

Summary

How does BioVie compare to Instil Bio?

Do institutionals & insiders have more ownership in BIVI or TIL?

Is BIVI or TIL more profitable?

Do analysts recommend BIVI or TIL?

Which has more risk and volatility, BIVI or TIL?

Which has higher earnings and valuation, BIVI or TIL?

Does the media refer more to BIVI or TIL?

Summary

How does BioVie compare to InterCure?

Does the media prefer INCR or BIVI?

Do analysts rate INCR or BIVI?

Is INCR or BIVI more profitable?

Which has more volatility & risk, INCR or BIVI?

Which has stronger valuation & earnings, INCR or BIVI?

Do insiders & institutionals hold more shares of INCR or BIVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI vs. The Competition

BioVie Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools